Respiratory Handbook 2005-15: Novartis Moving Into the Major League
Report
The respiratory market has experienced below average growth in the last five years (CAGR, 10%) reaching $25.5bn in 2004 in the seven major pharmaceutical markets.
The respiratory market has experienced below average growth in the last five years (CAGR, 10%) reaching $25.5bn in 2004 in the seven major pharmaceutical markets. Future growth will be essentially flat over the next 10 years (CAGR, 0.6%), estimated to reach $27.1bn in 2015. However, based on the current product pipeline, the position of the key players is expected to change dramatically.
Scope of this report
Asthma, COPD and allergic rhinitis indications; corticosteroids, beta-2 agonists, leukotriene modifiers, antimuscarinics and antihistamines classes
Overview of the current respiratory market situation, identifying the leading therapies, companies, indications and drug classes
Analysis of the potential impact of pipeline therapies on the respiratory market, and sales forecasts by indication to 2015
Performance of key respiratory players to 2015 (GSK, Pfizer, Boehringer Ingelheim, AstraZeneca, Merck, Schering-Plough, Sanofi-Aventis, Novartis)
Research and analysis highlights
The respiratory market is dominated by seven multinational drug companies, with combined 2004 revenues of $18.7bn representing 73% of total sales. GlaxoSmithKline is the global leader with 2004 sales in excess of $7bn, over $4.5 billion higher than the nearest rival, Merck.
The asthma/COPD market is expected to reach $18.1bn by 2015, with sales shifting towards COPD, which will account for 42% of revenues, following the launch of new products. Roughly 50% of asthma/COPD sales will result from products currently in development, largely replacing sales lost through the patent expiries of Advair/Seretide and Singulair.
The most significant launches over the next ten years will be GSK's once-daily inhaled corticosteroid/long-acting beta-2 agonist combination "Super Advair", Novartis' long-acting, dual-action bronchodilator combination product, GSK's novel intranasal corticosteroid, Allermist and Merck's Singulair/PG-D2 combination product.
Key reasons to read this report
Examine the success of currently marketed products in terms of their current and forecasted sales to 2015
Enhance future strategic planning by benchmarking the current and future performance of key players in the respiratory market
Predict the future direction of the respiratory market based on the potential of products in the pipeline
The respiratory market has experienced below average growth in the last five years (CAGR, 10%) reaching $25.5bn in 2004 in the seven major pharmaceutical markets.